7:33 am - Tuesday October 17, 2017

India will Now Help Protect Over 5 Million Children from the Life-threatening Pneumococcal Disease

Comments Off on India will Now Help Protect Over 5 Million Children from the Life-threatening Pneumococcal Disease
Business Wire India

  • Pfizer’s PCV 13 vaccine selected for inclusion in expansion of India’s immunization program. Phase 1 immunization program to cover 20% of around 26 million children[1] of India’s birth cohort under the Gavi funded program

Pfizer announced that its 13-valent Pneumococcal Conjugate Vaccine has been selected for inclusion in India’s immunization program in select states. In the first phase, the program will cover approximately 5.15 million babies – 20% of around 26 million children of India’s birth cohort. Globally, pneumococcal disease is one of the leading causes of deaths in children younger than 5 years of age. In India, according to the Farooqui article published in 2015, approximately 105,000 children had died of pneumococcal pneumonia in 2010.

The 13-valent Pneumococcal Conjugate Vaccine (PCV 13) is the most widely used pneumococcal conjugate vaccine in the world, with deployment in over 100 countries’ immunization program. PCV 13 vaccine provides the broadest serotype coverage including those serotypes most prevalent in India.

Epidemiological studies conducted in India[2] confirm that the PCV 13 vaccine provides higher coverage than any other PCV vaccine. The additional strains that PCV 13 covers are 3, 6A and 19A.  
 
PCV 13 will be introduced in a multi dose vial format in India. This presentation has been specially developed by Pfizer to enhance efficiencies of public immunization programs.

“The Government of India has made reaching every child with vaccines as a key priority. With the introduction of PCV 13, we will able to help protect India’s birth cohort of 26 million[3] children from the leading cause of child deaths in the country. Pfizer remains committed to supporting the Government and its partners in expanding the introduction of PCV 13 in the country such that every child in India gets access to protection from pneumococcal diseases”, said S. Sridhar, Country Manager, Pfizer India.

For the first phase, the vaccine will be supplied directly by Pfizer Inc. through UNICEF, under the auspices of Gavi, the Vaccine Alliance’s Advance Market Commitment – an innovative funding mechanism that provides Gavi eligible and Gavi graduated countries with access to advanced life-saving vaccines.

Pfizer Vaccines in the Developing World

Accelerating the availability of potentially life-saving vaccines around the world is a key component of Pfizer’s commitment to providing global access to health care. Through its participation in international public-private programs, Pfizer provides its 13-valent pneumococcal conjugate vaccine, Prevenar 13®, to infants and young children in the developing world to help protect against invasive pneumococcal disease. Since 2010, more than 45 of Gavi eligible countries have launched pneumococcal immunization programs with Prevenar 13®, via the Advance Market Commitment. With continued investment in research and development, Pfizer helps meet the challenges of the developing world by providing innovative manufacturing, storage, inventory management, and supply chain solutions. Apart from partnering with Ministries of Health to support disease awareness campaigns, Pfizer also continues to develop and deliver educational materials to aid health care workers in the field and conducts surveillance studies to understand the impact of pneumococcal immunization programs on reducing the burden of disease. For more information on Pfizer Vaccines in the Developing World, go to http://www.pfizer.com/health/vaccines/global-impact.
About Prevenar 13®  
                                                                                                                           

Prevenar 13® is the most widely used pneumococcal conjugate vaccine in the world, and is included in the pediatric National Immunization Programs in over 100 countries. In addition, Prevenar 13® is approved for use in adults 50 years of age and older in more than 100 countries. It is also approved in the United States, EU (European Union) and other countries for use in older children and adolescents aged 6 to 17 years. Prevenar 13® is also approved in the EU for use in adults 18 to 49 years of age.”

*Trademark. Prevnar 13® is the trade name in the United States, Canada, and Taiwan.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.  


[2] PneumoNET, PIDOPS and ASIP studies

Don't miss the stories followThe CEO Magazine and let's be smart!
Loading...
0/5 - 0
You need login to vote.

AURAK Signs MoU with University of Illinois

prev-next.jpg

Gen Re Receives Reinsurance Branch License in India

Related posts
Comments are closed